reports
Press Release: Sanofi and Novavax announce co-exclusive licensing agre...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with ...
Communiqué de presse : Sanofi et Novavax concluent un accord de licenc...
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale des deux entreprises, permettra aux patients de bénéficier à partir de 2025 d’un meilleur accès à un vaccin adjuvanté à base de protéines, non-ARNm, contre la COVID-19 Accélération du ...
23andMe to Report Q4 and Full Year FY2024 Financial Results
23andMe to Report Q4 and Full Year FY2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year’s financial ...
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 1,385 shares at 128.760USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 9 May 2024 Transaction in Own Shares The Company announces that on 8 May 2024 it bought back 20,000 of its own shares, to be held as treasury shares, at an average price of 1187 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 6,373,133.Total shares in issue excluding treasury shares following settlement of this purchase: 66,539,867. The Company has bought back these shares under the authority granted by shareholders at its Annual Genera...
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Lev...
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigatio...
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
UCG UNICREDIT S.P.A.
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Damien Choplain
- Martial Descoutures
AstraZeneca : A consensus that leaves little room for surprising guida...
>The premium can be justified by short-term growth and a well-stocked pipeline - AZN certainly benefits from: i/ attractive short-term core EPS growth for 2023-2027, up 11.5% (+12.7% expected this year), and undoubtedly the most well-stocked pipeline in the industry. These elements partly justify the market premium for its 2025 P/E (+43% vs sector median), leading to a 2023-2027 PEG of 1.6x vs 1.3x for the sector. However, this growth should be more timorous in 2...
ICG Enterprise Trust Plc: Preliminary Results for the twelve months en...
ICG Enterprise Trust Plc: Preliminary Results for the twelve months ended 31 January 2024 ICG Enterprise Trust plcPreliminary Results for the twelve months ended 31 January 20248 May 2024 Portfolio companies performing strongly Highlights NAV per Share of 1,909p, LTM NAV per Share Total Return* of 2.1% and 5-year annualised return of 14.6%Portfolio companies reporting strong operational performance1: 14.2% LTM EBITDA growth and prudent leverage of 4.6xFY24 Portfolio Return* on a Local Currency Basis of 5.9%; FX movements resulted in a Portfolio Return on a Sterling Basis of 3.2%E...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 8 May 2024 Transaction in Own Shares The Company announces that on 7 May 2024 it bought back 20,000 of its own shares, to be held as treasury shares, at an average price of 1204 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 6,353,133.Total shares in issue excluding treasury shares following settlement of this purchase: 66,559,867. The Company has bought back these shares under the authority granted by shareholders at its Annual Genera...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Un consensus qui ne laisse que peu de place à une guidan...
>Une prime qui se justifie par une croissance CT et un pipeline exhaustif - AZN bénéficie sans nulle doute i/ d’une croissance CT attractive Core BPA 2023-2027 en hausse de 11.5% (+12.7% att cette année) et d’un pipeline certainement le plus exhaustif de l’industrie. Ces aspects justifient en partie la prime octroyée par le marché en termes de PE 25e (+43% vs médiane sectorielle) conduisant à un PEG 23/27e de 1.6x vs 1.3x pour le secteur. En revanche cette croiss...
Ipsen S.A. - Formalities for making available and consulting preparato...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BILLANCOURT, FRANCE, 7 May 2024 - The Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Tuesday 28 May 2024 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et M...
IPSEN SA. - Modalités de mise à disposition et de consultation des doc...
IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024 Informations concernant la tenue de l’Assemblée Générale Mixte du 28 mai 2024 d’Ipsen S.A. Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée BOULOGNE-BILLANCOURT, FRANCE, 7 mai 2024 - Les actionnaires de la Société sont invités à participer à l’Assemblée Générale Mixte d’Ipsen (Euronext : IPN ; ADR : IPSEY), qui se tiendra le mardi 28 mai 2024 à 15h00 (heure de Paris) aux Salons d...
Q&A on City of London Investment Group (CLIG): Funds under management ...
Hardman & Co Research Q&A on City of London Investment Group (CLIG): Funds under management boosted by positive inflows 07-May-2024 / 10:27 GMT/BST The issuer is solely responsible for the content of this announcement. Analyst interview | Investment Companies Q&A on City of London Investment Group | Funds under management boosted by positive inflows City of London Investment Group (CLIG) is the topic of conversation when Brian Moretta, analyst at Hardman & Co, joins DirectorsTalk Interviews. With CLIG recently announcing its third quarter FUM update Brian talks through Cit...
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 6,311,250 shares at 860.020DKK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Adrian Loh Tzum Yung
- Chong Lee Len
- Jacquelyn Yow Hui Li
- Leow Huey Chuen
- Llelleythan Tan Tan
Singapore Daily: Tuesday, May 7, 2024
KEY HIGHLIGHTS Sector Offshore Marine Bullish view remains despite recent volatility in the Middle East. Update StarHub (STH SP/BUY/S$1.18/Target: S$1.41) Favourable tailwinds as DARE+ initiatives bear fruit, with investments peaking in 2024. Wilmar International (WIL SP/HOLD/S$3.22/Target: S$3.35) 2Q24 earnings to be higher qoq and yoy. Investors can consider buying on weakness. TRADERS' CORNER Keppel DC REIT (KDCREIT SP):...
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the web...
Ipsen - Monthly information relative to the total number of voting rig...
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 Apr...
Ipsen - Information mensuelle relative au nombre total des droits de v...
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)30 avril 202483 814 526Total brut* des droits de vote : 132 1...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.